Skip to main content Skip to navigation
We care about your privacy. Read about your rights and how we protect your data. Get Details

Education & Training

  • Fellowship, Pediatric Hematology-Oncology, 1997
    Johns Hopkins Hospital
  • Residency, Pediatrics, 1994
    Yale New Haven Hospital
  • Internship, Pediatrics, 1992
    Yale New Haven Hospital
  • MD, 1991
    University of Pennsylvania School of Medicine
  • BA, 1987
    University of Pennsylvania

Board Certifications

  • American Board of Pediatrics/Hematology-Oncology

Awards & Recognition

  • Top Doctors Washingtonian (2021, 2020, 2019)
  • Top Doctors No Va Magazine (2023, 2022, 2021)

National Provider ID: 1902809197


Jeffrey Dome, M.D., Ph.D., is Senior Vice President of the Center for Cancer and Blood Disorders and Chief of the Division of Oncology at Children’s National Hospital in Washington, D.C. He also is Professor of Pediatrics at the George Washington University School of Medicine & Health Sciences and the Thomas Willson and Lenore Williams McKnew Professor of Pediatric Oncology. Dr. Dome received his M.D. degree from the University of Pennsylvania School of Medicine and his Ph.D. degree in Medicine from Erasmus University in Rotterdam. He completed a residency in Pediatrics at Yale-New Haven Hospital and a fellowship in Pediatric Hematology/Oncology at Johns Hopkins Hospital.

After fellowship, Dr. Dome was a faculty member at St. Jude Children’s Research Hospital before joining Children’s National Hospital in 2006. Dr. Dome is an internationally recognized expert on pediatric solid tumors, with an emphasis on kidney tumors and sarcomas. He chaired the Children’s Oncology Group (COG) Renal Tumor Committee, which oversees clinical research on kidney tumors at more than 200 children’s hospitals around the world, for more than 10 years. Dr. Dome is the Continental President of North America for the International Society of Paediatric Oncology (SIOP). He is a member of the Hematology/Oncology Sub board of the American Board of Pediatrics and serves on numerous medical advisory boards for cancer foundations. He has authored more than 150 articles, books and chapters on pediatric cancer.

This faculty member (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.

Outside Interests

  • American Board of Pediatrics 
  • St Jude Children's Research Hospital 
  • Sigma-Tau Pharmaceuticals,, Inc. 

Research & Publications

Age at diagnosis as a prognostic factor for rhabdoid tumor of the kidney A report from the National Wilms Tumor Study Group

(2005) Journal of Clinical Oncology

Disappearance of the Telomere dysfunction induced stress response in fully senescent cells

(2004) Cancer Research

High telomerase RNA expression is an adverse prognostic factor for favorable histology Wilms tumor

(2005) Journal of Clinical Oncology

Improved survival for patients with recurrent Wilms tumor

(2002) Journal of Pediatric Hematology Oncology

Recent advances in Wilms tumor genetics

(2002) Current Opinion in Pediatrics

Telomerase expression predicts unfavorable outcome in osteosarcoma

(2004) Journal of Clinical Oncology

Telomere biology of pediatric cancer

(2007) Cancer Investigation

The feasibility and outcome of nephron-sparing surgery for children with bilateral Wilms tumor The St Jude Childrens Research Hospital Experience 19992006

(2008) Cancer

Topotecan is active against Wilms tumor Results of a multi-institutional phase II study

(2007) Journal of Clinical Oncology

Treatment of Anaplastic Histology Wilms Tumor Results from the Fifth National Wilms Tumor Study

(2006) Journal of Clinical Oncology